FPRX Five Prime Therapeutics Inc.

10.53
-0.4  -4%
Previous Close 10.93
Open 10.92
Price To Book 1.26
Market Cap 373454053
Shares 35,465,722
Volume 185,042
Short Ratio
Av. Daily Volume 417,664

SEC filingsSee all SEC filings

  1. 8-K - Current report 19527210
  2. 8-K - Current report 19512096
  3. CT ORDER - Confidential treatment order 181242378
  4. 8-K - Current report 181208593
  5. S-3 - Registration statement under Securities Act of 1933 181163310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 portion of Phase 1/3 trial has been initiated - September 10, 2018. Phase 1 data presented at ASCO GI January 17, 2019 noted 19% ORR.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
FP-1039
Mesothelioma cancer
Phase 1 commencement of dosing announced March 28, 2018. Data to be presented 2019.
FPA150
Solid tumors
Phase 2 trial initiated January 2018.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 dosing announced November 14, 2018. Data due 2019.
FPT155
Solid tumors

Latest News

  1. See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
  2. Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
  3. Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications
  4. Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
  5. Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities
  6. Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium
  7. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  8. Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  9. Five Prime Therapeutics Announces Changes to its Board of Directors
  10. 3 Top Biotech Stocks to Buy Right Now
  11. Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
  12. Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT
  13. Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein
  14. Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more
  15. New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Consolidated Revenues, Company Growth, and Expectations for 2018

SEC Filings

  1. 8-K - Current report 19527210
  2. 8-K - Current report 19512096
  3. CT ORDER - Confidential treatment order 181242378
  4. 8-K - Current report 181208593
  5. S-3 - Registration statement under Securities Act of 1933 181163310
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163220
  7. 8-K - Current report 181163076
  8. 8-K - Current report 181158943
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 181130476
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181108473